home / stock / nonof / nonof news


NONOF News and Press, Novo-Nordisk A/S From 02/13/24

Stock Information

Company Name: Novo-Nordisk A/S
Stock Symbol: NONOF
Market: OTC
Website: novonordisk.com

Menu

NONOF NONOF Quote NONOF Short NONOF News NONOF Articles NONOF Message Board
Get NONOF Alerts

News, Short Squeeze, Breakout and More Instantly...

NONOF - Eli Lilly partner BioAge wins $170M to study Zepbound combo

2024-02-13 13:07:35 ET More on Eli Lilly Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript Federal judge...

NONOF - Federal judge dismisses PhRMA challenge to Medicare price negotiations

2024-02-12 21:01:27 ET More on Bristol-Myers Squibb Company , Eli Lilly, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Will Eli Lilly and Company Become A Trillion-Dollar Baby? RayzeBio ticks higher af...

NONOF - Novo Nordisk's parent eyes $7B annual investments by 2030: FT

2024-02-12 08:41:44 ET More on Novo Nordisk Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Booming weight-loss drug market to lift “pick-and-shovel...

NONOF - Booming weight-loss drug market to lift "pick-and-shovel" plays: Jefferies

2024-02-11 12:00:03 ET More on Eli Lilly, Novo Nordisk, etc. Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript ...

NONOF - Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)

2024-02-07 18:00:06 ET Summary Eli Lilly and Company has seen significant growth and generated strong returns, outperforming the S&P 500. The company's revenue increased by 28.1% in the final quarter of 2023, exceeding analysts' expectations. While some drugs, like Trulici...

NONOF - Novo Nordisk CEO wins 13% raise amid soaring demand for weight loss drugs

2024-02-07 13:52:09 ET More on Novo Nordisk Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Lilly reportedly worried about impact of Catalent/Novo deal ...

NONOF - Amgen cut at Leerink on heavy obesity expectations

2024-02-07 09:34:00 ET More on Amgen Amgen Inc. (AMGN) Q4 2023 Earnings Call Transcript Amgen: Debt-Funded Buybacks Constrains Future Gains Per Share Amgen: Accelerating The Business And Dividend Growth Amgen Non-GAAP EPS of $4.71 beats by $0.12, revenue of $...

NONOF - Eli Lilly beats in Q4 as obesity drug sales blow past estimates

2024-02-06 07:25:47 ET More on Eli Lilly Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Biotech And Pharma Diversification Pays Off Eli Lilly: The Cupboard Is Fully Stocked Eli Lilly beats top-line and bottom-line estimates; ...

NONOF - Novo-Catalent deal to ease Wegovy supply concerns

2024-02-05 15:46:06 ET More on Catalent, Novo Nordisk, etc. Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Biggest stock movers today: Nvidia, Air Product...

NONOF - Eli Lilly Q4 results to highlight Zepbound uptake

2024-02-05 12:38:30 ET More on Eli Lilly Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Biotech And Pharma Diversification Pays Off Eli Lilly: The Cupboard Is Fully Stocked Eli Lilly sees highest intraday trade since November...

Previous 10 Next 10